In SLE patients, IFN-α can prime monocytes for enhanced NLRP3 inflammasome activity and IL-1β production in an IRF-1-dependent manner [101], and neutrophils for NETosis upon exposure to SLE-derived anti-ribonucleoprotein antibodies [96]. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.